4 November 2026
Oxford Nanopore Technologies plc
("Oxford Nanopore" or the "Company")
Oxford Nanopore to participate in upcoming investor conferences
Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new generation of molecular sensing technology based on nanopores, will be participating in the following investor conferences in November.
· Stifel Healthcare Conference, New York
Format: Fireside chat and investor meetings
Date: Tuesday, 10 November
Nick Keher, Chief Financial Officer, will participate in an analyst led fireside chat at 1:20pm EST (6:20pm GMT).
· Canaccord Medtech, Diagnostics and Digital Health & Services Forum, New York
Format: Fireside chat and investor meetings
Date: Wednesday, 11 November
Nick Keher, Chief Financial Officer, will participate in an analyst led fireside chat at 11:30am EST (4:30pm GMT).
· Jefferies Global Healthcare Conference, London
Format: Presentation and Q&A session, and investor meetings
Date: Tuesday, 17 November
Francis Van Parys, Chief Executive Officer, will deliver a presentation at 11:00am GMT (6:00am EST), followed by a Q&A session with Nick Keher, Chief Financial Officer.
· Berenberg European Conference, Windsor
Format: Fireside chat and investor meetings
Date: Monday, 30 November
Francis Van Parys, Chief Executive Officer, and Nick Keher, Chief Financial Officer, will participate in an analyst led fireside chat at 1:15pm GMT.
Webcasts of the Stifel and Canaccord fireside chats and Jefferies presentation and Q&A session will be accessible through Oxford Nanopore's Investor Relations website. The webcasts will be available for replay for at least 30 days after the event.
-ENDS-
For further information, please contact:
Oxford Nanopore Technologies plc
Investors: [email protected]
Media: [email protected]
Teneo (communications adviser to the Company)
Tom Murray, Lisa Jarrett-Kerr
+44 (0) 20 7353 4200
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.
For more information please visit: www.nanoporetech.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.